Vedolizumab Pharmacovigilance Knowledge Assessment

Classify the event as treatment failure solely because symptoms occurred during therapy. Assume the event is an adverse drug reaction because the treatment was intended to control intestinal inflammation. Assess disease activity, infection, adherence, treatment schedule, prior response, concomitant therapy and objective findings before assigning causality. Exclude disease flare because the patient is receiving a biological medicine.

It ensures that every event is attributed to treatment. It allows reviewers to distinguish pre-existing abnormalities, evolving disease, treatment-associated changes and outcomes over time. It eliminates the need to document concomitant medicines. It makes all cases directly comparable regardless of indication.

Mechanism-led review replaces clinical judgment and alternative-cause assessment. Mechanism-led review identifies relevant phenotypes and follow-up needs, while causality still depends on the complete clinical and exposure evidence. Mechanism-led review is useful only during pre-authorisation development. Mechanism-led review requires that all events be classified under one broad immune-mediated category.

Because these factors are never relevant to infection risk but are required for database completion. Because they may provide important alternative or contributing explanations for infection susceptibility and severity. Because their presence proves that vedolizumab is unrelated to the infection. Because they replace the need for microbiological confirmation.

The patient's batch number alone. Concurrent antibiotics, corticosteroids, hospital care, rescue therapy or natural fluctuation of the disease. The existence of a product information document. The use of structured case fields.

Use total preferred-term counts without considering indication or treatment phase. Stratify relevant populations and regimens, examine clinical syndromes rather than isolated terms, and compare findings with background rates and exposure denominators. Treat every increase in reporting as proof of a new causal risk. Exclude concomitant medicines because they are not part of the active substance.

As a mandatory step for every suspected adverse reaction. As definitive proof of causality whenever the event recurs. As potentially informative evidence when it occurs, but not as a procedure that should be deliberately undertaken merely to test causality. As evidence against causality if the patient is re-exposed without immediate recurrence.

Because gut selectivity proves that neurological and hepatic events are caused by vedolizumab. Because target selectivity reduces the need for clinical follow-up but eliminates the need for causality assessment. Because patients may still experience infections, administration reactions, neurological symptoms, liver abnormalities, immunogenicity or disease-related events requiring evaluation. Because gut-selective medicines are expected to produce more systemic immunosuppression than non-selective therapies.

Broader indications, new age groups, new devices, switching patterns, combination regimens or longer exposure. The continued use of the same database coding conventions without review. Removal of treatment-phase information from case narratives. Using the same exposure denominator regardless of population or regimen.

Preferred terms always identify the underlying mechanism with certainty. Several terms may describe one clinical syndrome, while one term may combine events with different mechanisms and severity. Preferred terms are relevant only for quality complaints and never for adverse events. Counting terms automatically adjusts for exposure duration and patient characteristics.